Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Neovasc (NVCN) has finalised the design of the Transfemoral Trans-Septal Tiara (TF/TS Tiara) system, for treatment of the heart condition called mitral valve disease.
  • The design freeze of the product now includes a modified, lower profile valve, and a steerable delivery system.
  • The TF/TS Tiara is designed to be minimally invasive, self-anchoring, trackable, and fully retrievable.
  • The company hopes to start a clinical study on the product’s feasibility in late 2020.
  • Neovasc’s share price is down 2.77 per cent, with shares currently trading at $3.51 apiece.

Specialty medical device company Neovasc (NVCN) has finalised the design for the Transfemoral Trans-Septal Tiara (TF/TS Tiara) system.

The Neovasc Tiara device is for treating a heart condition called mitral valve disease, or mitral regurgitation. 

The design freeze for the product includes a number of changes, including a modified, lower profile valve, and a steerable delivery system. These changes may expand the pool of potential patients who are eligible for treatment.

The TF/TS Tiara system’s final design is minimally invasive, self-anchoring, trackable, and fully retrievable. President and CEO of Neovasc, Fred Colen described the product as a potential “best-in-class system.”

The Tiara is currently under clinical investigation in the United States, Canada, Israel, and Europe. Neovasc expects that they will be able to start a clinical study on the product’s feasibility in late 2020.

Neovasc’s share price is down 2.77 per cent, with shares currently trading at $3.51 apiece at 2:43pm EST.

More From The Market Herald

" Revive Therapeutics (CSE:RVV) updates Bucillamine in treating COVID-19

Revive Therapeutics (RVV) announced an update of its Food and Drug Administration (FDA) phase three clinical trial for Bucillamine.
The Market Herald Video

" BioVaxys (CSE:BIOV) signs binding term sheet for distribution of Papilocare in the U.S.

BioVaxys Technology Corp. (BIOV) has signed a binding term sheet with Procare Health Iberia, S.L. of Barcelona, Spain.

" Satellos Bioscience (TSXV:MSCL) announces OTCQB listing

Common shares of Satellos Bioscience (MSCL) have commenced trading on the OTCQB Venture Market (OTCQB) under the symbol MSCLF.
Innocan Pharma - CEO Iris Bincovish

" Innocan Pharma (CSE:INNO) patent application for treatment of psoriasis of the scalp goes national

Innocan Pharma’s (INNO) patent application, which claims cannabinoid-based topical compositions can treat psoriasis of the scalp, has reached the national phase.